AnaptysBio
Transforming patient health by delivering innovative immunology therapeutics.
Transforming patient health by delivering innovative immunology therapeutics.
AnaptysBio is a biotechnology startup based in the United States that was founded in 2005. The company's slogan "Transforming patient health by delivering innovative immunology therapeutics" encapsulates their mission to make a difference in the lives of people living with autoimmune and inflammatory diseases. AnaptysBio is a clinical-stage biotechnology company dedicated to discovering and developing innovative immunology therapeutics. They have a broad portfolio of immune cell modulators, including two checkpoint agonists in clinical-stage development. In July 2015, AnaptysBio received a significant boost with a $40.00M Series D investment from a group of prominent investors, namely HBM Healthcare Investments, Frazier Healthcare Partners, BVF Partners, Cormorant Asset Management, and BioMed Ventures. This substantial investment underscores the confidence these reputable investors have in AnaptysBio's potential to deliver transformative solutions in the field of immunology therapeutics. With its robust portfolio and strong backing, AnaptysBio is well-positioned to continue its efforts in advancing novel therapeutics and positively impacting patient health.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series D | $40.00M | 5 |
|
15 Jul 2015 |
| Debt Financing | $2.02M | - | 30 Aug 2013 | |
| Series C | $8.02M | - | 14 Oct 2011 | |
| Series B | $33.90M | 5 |
|
08 Nov 2007 |
| Series A | $2.00M | - | 31 Jul 2006 |
No recent news or press coverage available for AnaptysBio.
We care about your data, and we'd love to use cookies make your experience better.
